Posted by Michael Wonder on 02 Feb 2017
BioMarin receives Access to Priority Medicines (PRIME) regulatory support from EMA for BMN 270 gene therapy in haemophilia A
1 February 2017 - First product to be eligible for access to PRIME in haemophilia.
BioMarin announced today that the EMA has granted access to its Priority Medicines (PRIME) regulatory initiative for the company's investigational gene therapy treatment for severe haemophilia A, BMN 270.
To be accepted for PRIME, an investigational therapy has to show its potential to benefit patients with unmet medical needs based on early clinical data.
